Table 4 Response criteria: SF-36 scores at baseline and at study assessment time points
Variable | Canakinumab 150 mg SC q4wk, n = 71 | Canakinumab 300 mg SC q2wk, n = 64 | Canakinumab 300 mg SC q2wk + 600 mg IV loading dose, n = 69 | Placebo, n = 70 |
|---|---|---|---|---|
Mean SF-36 physical component summary score | ||||
Baseline, mean (SD) | 27.19 (7.092) | 28.57 (7.497) | 26.29 (6.080) | 27.48 (6.616) |
Week 2, mean (SD) | 29.70 (7.944) | 28.94 (7.503) | 27.86 (6.441) | 29.58 (8.438) |
Week 4, mean (SD) | 30.40 (8.400) | 30.87 (8.608) | 28.91 (8.445) | 29.94 (8.413) |
Week 8, mean (SD) | 31.48 (9.833) | 31.32 (8.230) | 28.89 (7.322) | 29.44 (8.569) |
Week 12, mean (SD) | 32.92 (9.922) | 31.62 (8.752) | 30.33 (7.129) | 30.17 (9.221) |
Mean SF-36 mental component summary score | ||||
Baseline, mean (SD) | 44.38 (12.891) | 43.40 (11.325) | 41.61(10.845) | 44.64(12.779) |
Week 2, mean (SD) | 45.94 (12.518) | 46.02 (11.083) | 42.37 (10.585) | 45.09 (12.834) |
Week 4, mean (SD) | 46.61 (12.469) | 46.14 (12.008) | 43.85 (11.433) | 46.16 (12.835) |
Week 8, mean (SD) | 47.41 (12.228) | 46.22 (12.762) | 44.09 (11.849) | 45.82 (12.032) |
Week 12, mean (SD) | 48.44 (12.421) | 46.74 (11.595) | 43.05 (11.958) | 44.99 (12.294) |